Genprex

Category: Press Releases

Genprex to Present in November CEO Roadshow Webinar

Presentation to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

Read More

Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clincial trials of REQORSA systemic gene therapy in non-small cell lung cancer and works to expand technology pipeline

Read More

Genprex to Participate in September Investor Conferences

Presentations to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

Read More

Genprex to Participate in a Monthly CEO Roadshow Webinar Series

Series to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

Read More

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex announced that the FDA has confirmed all comments have been addressed regarding the Company’s protocol for the Acclaim-1 clinical trial

Read More

Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series

Investor presentation to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer

Read More

Genprex to Participate in Upcoming May Investor Conferences

Investor presentations to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer

Read More

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer

Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise

Read More


Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Acclaim-2 Clinical Trial Combines REQORSA™ immunogene therapy with Merck & Co’s Keytruda®

Read More